Stay updated on Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T05:45:31.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T07:57:59.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The study page for NCT03595683 now shows a 403 Forbidden error, replacing the expected content with an access-denied message and preventing access to the study details.
    Difference
    19%
    Check dated 2026-09-20T03:17:38.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, representing a new version of the ClinicalTrials.gov record. This revision does not change the study data or eligibility details.
    Difference
    0.1%
    Check dated 2026-08-29T23:40:21.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    Revision bumped from v3.6.4 to v3.6.5, reflecting a minor page version update. It does not modify study content or user-facing information.
    Difference
    0.1%
    Check dated 2026-08-08T23:44:12.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    The page's version tag was updated from v3.6.3 to v3.6.4, signaling a minor platform update with no changes to the study details.
    Difference
    0.1%
    Check dated 2026-07-25T16:43:07.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.